TPFmORL (GORTEC 2019-01)

Randomized phase II study comparing induction chemotherapy combining cisplatin, 5-Fluorouracil and docetaxel at modified doses (TPFm) or standard doses (TPF) in patients with locally advanced squamous cell ENT cancer
Coordinator : Dr Fayette
Start date : not started March 2019
Number of patients : 167

Access detailed information on the trial in the private section

 

REWRITe (GORTEC 2018-02)

A phase II trial evaluating radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck
Coordinator : Prof. BOURHIS
Start date : not started March 2019
Number of patients : 73

Access detailed information on the trial in the private section

 

NIVO POST OP (GORTEC 2018-01)

Phase III randomized trial of post-operative adjuvant nivolumab and concomitant cisplatin-radiotherapy (standard of care) in patients with locally advanced resected squamous cell carcinoma of the head and neck (SCCHN) at high risk of recurrence
Coordinator : Prof. BOURHIS
Start date : 2018
Number of patients : 484 (242 per arm)

Access detailed information on the trial in the private section

 

FRAILIMMUNE (GORTEC 2018-03)

Multicenter, prospective, single-arm phase II study evaluating the efficacy and safety of Durvalumab with Carboplatin and Paclitaxel as first-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck not eligible for standard chemotherapy
Coordinator : Dr Fayette
Start date : not started March 2019
Number of patients : 102

Access detailed information on the trial in the private section

 

STEREO-POSTOP (GORTEC 2017-03)

Multicenter, phase II study of postoperative hypofractionated stereotactic radiotherapy in the treatment of localized oropharyngeal and oral cavity cancers with high risk margins
Coordinator : Dr Biau
Start date : 2018
Number of patients : 90

Access detailed information on the trial in the private section

 

SIMPA 01 (GORTEC 2017-02)

Double-blind, multicenter, phase III study evaluating the efficacy of an oral immune modulating formula on survival during postoperative concomitant chemo-radiotherapy in head and neck squamous cell carcinoma
Coordinator : Dr Senesse
Start date : not started March 2019
Number of patients : 306

Access detailed information on the trial in the private section

 

REACH (GORTEC 2017-01)

Phase III randomized trial of avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous cell carcinoma of the head and neck
Coordinator : Prof. BOURHIS
Start date : 2017
Number of patients : 688

Access detailed information on the trial in the private section

 

SANTAL (GORTEC 2016-02)

Phase III randomized trial of chemo-radiotherapy versus radiotherapy alone in the treatment of sinus and salivary gland tumors
Coordinator : Dr François-Régis FERRAND
Start date : 2017
Number of patients : 260 (130/arm)

Access detailed information on the trial in the private section

 

PembroRad (GORTEC 2015-01)

Phase II randomized study to determine the tolerance and efficacy of Pembrolizumab or Cetuximab combined with radiation therapy in patients with locally advanced squamous cell carcinoma of the head and neck.
Coordinator : Prof. BOURHIS
Start date : 2016
Number of patients : 132 patients (66 per arm)

Access detailed information on the trial in the private section

 

CisFRAD (GORTEC 2015-02)

Phase II randomized study of RT cisplatin 100 versus weekly fractionated.
Coordinator : Dr Borel
Start date : 2016
Expected number of patients : 124

Access the Clinical Trials link

Access detailed information on the trial in the private section

 

OMET study (GORTEC 2014-04)

Role of stereotactic radiotherapy in patients with oligometastases.
Coordinator : Prof. Sun
Start date : 2015
Expected number of patients : 78

Access the Clinical Trials link

Access detailed information on the trial in the private section

 

SALTORL study (GORTEC 2014-03)

Assessment of survival without laryngeal-esophageal dysfunction after 2 years in patients with resectable carcinoma of the larynx or hypopharynx.
Coordinator: Prof. Calais
Start date : 2015
Expected number of patients : 440

Access the Clinical Trials link

Access detailed information on the trial in the private section

 

RADAR study (GORTEC 2014-02)

Observational study: preventive treatment of radiation dermatitis associated with radiotherapy + cetuximab.
Coordinator: Prof. Lartigau
Start date : 2015
Expected number of patients : 70

Access the Clinical Trials link

Access detailed information on the trial in the private section

 

IMPATOX

Phase III trial evaluating the benefit of an oral immune modulating solution in the prevention of severe acute mucositis following chemotherapy
Coordinator : Dr SENESSE - Dr BOISSELIER
Start date : 2012
Number of patients    160

Access the Clinical Trials link

Access detailed information on the trial in the private section